Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03109561
Other study ID # 17-0202-F1G
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 24, 2018
Est. completion date January 30, 2020

Study information

Verified date July 2020
Source University of Kentucky
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Impaired metabolism and the gene apolipoprotein E (ApoE) are independent risk factors for cognitive impairment and dementia. In humans, there are three major versions of apoE (E): E2, E3, and E4. Some studies suggest that the different versions of apoE have varying effects on whole body and brain metabolism. The goal of this project is to better understand the relationship between apoE and metabolism. This will help investigators identify new targets for the prevention and treatment of cognitive decline and dementia.


Description:

The investigator hopes determine whether a participant's version of ApoE affects their metabolic rate at rest and during a cognitive challenge. To determine this, the investigator will measure basal (resting) metabolic rates using a technique called indirect calorimetry (IC). This is accomplished by wearing a loose-fitting face mask that measures oxygen intake and carbon dioxide output.

To more accurately measure the amount of carbohydrates, fats and proteins that the body is metabolizing, participants will be asked to provide two urine samples (one at the beginning, and one at the end, of the study).

To determine what version of ApoE the participant inherited, the investigator will conduct a genetic test on DNA isolated from the participant's blood.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date January 30, 2020
Est. primary completion date January 30, 2020
Accepts healthy volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- all races/ethnicities

- ages 18-65

- cognitively normal

- good health

Exclusion Criteria:

- pregnant or breastfeeding.

- have a bleeding disorder,

- have a history of stroke, seizures, Parkinson's disease, history of head injury with loss of consciousness, or other dementing disorder.

- have a history of alcoholism or drug abuse

- have a history of schizophrenia or currently suffer from bipolar disorder or major depression.

- have vision or hearing loss severe enough to interfere with cognitive testing

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Resting State Indirect Calorimetry
The investigator will measure the amount of oxygen participants breathe in and the amount of carbon dioxide they breathe out using a portable unit. Participants will be asked wearing a loose-fitting face mask that measures oxygen intake and carbon dioxide output.
Genetic:
ApoE
The investigator will conduct a genetic test on DNA isolated from from the participants blood. Participants will be asked to provide about 2 tablespoons.
Diagnostic Test:
Metabolism
To more accurately measure the amount of carbohydrates, fats and proteins that the participants bodies metabolize, participants will be asked to provide two urine samples (one at the beginning, and one at the end, of the study). The total amount of urine to be collected is approximately 4 teaspoons.
Other:
Cognitive Challenge
Participants will be asked to follow simple instructions that are displayed on computer screen.

Locations

Country Name City State
United States University of Kentucky Medical Center Lexington Kentucky

Sponsors (1)

Lead Sponsor Collaborator
Lance Johnson

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Urea Nitrogen Output Improve RQ measure accuracy by determining urinary urea nitrogen output in collected urine samples from these subjects. 4 hours
Other Genotype Genotype subjects using DNA isolated from collected blood samples. 4 hours
Primary Indirect Calorimetry Measure resting state respiratory quotient in cognitively normal participants with various ApoE genotypes 4 hours
Secondary Respiratory Quotient (RQ) Measure RQ during a cognitive challenge in cognitively normal individuals with various ApoE genotypes 4 hours
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1